Table 1.
Patient characteristics at time of metastatic diagnosis and outcomes (n = 226)
| Characteristic | n = 226 |
|---|---|
| Age, yr | |
| Mean ± SD | 59 ± 13 |
| Median (25th, 75th percentile) | 59 (50, 68) |
| Minimum–maximum | 26–92 |
| Sex, n (%) | |
| Male | 119 (53) |
| Race and ethnicity, n (%) | |
| White | 204 (90) |
| Asian | 10 (4) |
| Black | 2 (1) |
| Hispanic or Latino | 1 (1) |
| Other | 3 (1) |
| Unavailable | 6 (3) |
| Weight at metastatic diagnosis, kg | |
| Mean ± SD | 80 ± 21 |
| Median (25th, 75th percentile) | 77 (66, 91) |
| Minimum–maximum | 43–153 |
| Height, cm | |
| Mean ± SD | 170 ± 11 |
| Median (25th, 75th percentile) | 168 (163, 178) |
| Minimum–maximum | 145–196 |
| Body mass index, kg/m2 | |
| Mean ± SD | 27.5 ± 5.6 |
| Median (25th, 75th percentile) | 26.5 (23.7, 30.5) |
| Minimum–maximum | 17.1–43.8 |
| Organ of cancer origin, n (%) | |
| Colon | 170 (75) |
| Rectum | 56 (25) |
| Location of tumor, n (%) | |
| Left | 149 (66) |
| Right | 64 (28) |
| Transverse | 13 (6) |
| Tumor mutation, n (%) | |
| Wild type | 99 (44) |
| KRAS | 86 (38) |
| NRAS | 9 (4) |
| BRAF (V600 mutations only) | 32 (14) |
| Therapy type of first treatment, n (%) | |
| Standard chemotherapy | 205 (91) |
| Targeted + standard chemotherapy | 21 (9) |
| No. of lines of systemic therapy after metastatic diagnosis | |
| Mean ± SD | 2.4 ± 1.5 |
| Median (25th, 75th percentile) | 2 (1, 3) |
| Minimum–maximum | 0–9 |
| First‐line metastatic chemotherapy regimens n (%) | |
| 5FU/capecitabine | 3 (1) |
| + bevacizumab | 2 (1) |
| FOLFOX | 70 (31) |
| + bevacizumab | 61 (27) |
| + EGFRi | 1 (0.4) |
| FOLFIRI | 13 (6) |
| + bevacizumab | 32 (14) |
| + EGFRi | 14 (6) |
| FOLFOXIRI | 16 (7) |
| + bevacizumab | 5 (2) |
| Irinotecan + bevacizumab | 1 (0.4) |
| None | 8 (4) |
| >5% loss at 3 mo, n (%) | |
| Weight | 43 (22) |
| Skeletal muscle | 57 (30) |
Abbreviations: EGFRi, epidermal growth factor inhibitor; 5FU, 5‐fluorouracil; IQR, interquartile range.